Executive Summary
Ondine Biopharma Corporation is developing non-antibiotic therapies for the treatment of bacterial, fungal and viral infections. The Company is focused on developing and commercializing innovative products using its patented light-activated technology. Photodynamic disinfection (PDD) provides broad-spectrum antimicrobial efficacy with minimal side effects and without encouraging the formation and spread of bacterial resistance. Ondine expects to first introduce the PERIOWAVE(TM) photodynamic disinfection system into the multi-billion dollar periodontal disease market, and then develop other applications in the treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) and other infections.
Company History
Current Events
Business Model
Products/Services
Segments/Customers
Production/Operations
Distribution/Routes to Market
Market & Competition
Market Share
Main Competitors
Competitive Strengths and Weaknesses
Management
Financials
Profit & Loss
Balance sheet
Cashflow
Valuation
Comparable Companies
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
